---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-22-000080"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:27:16.765757+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exagen reduces workforce by 42, estimates $750k in Q4 charges; CMO terminated

## Summary
- Board approved reduction in force of 42 employees, completed Dec 5, 2022, to conserve cash.
- Estimated pre-tax charges of ~$750k in Q4 2022 for severance, benefits, and related costs.
- CMO Debra Zack terminated; entitled to lump sum of ~$201.6k (6 months salary) plus COBRA reimbursement.
- Dr. Zack entered consulting agreement at $250/hr through Mar 31, 2023; unvested stock options continue to vest.
- COO Mark Hazeltine appointed Chief Business Officer, effective Dec 5, 2022.

## SEC filing metadata
- accession: 0001274737-22-000080
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000080/0001274737-22-000080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000080/exdx-20221205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-22-000080
- JSON: https://secwatch.observer/filing/0001274737-22-000080.json
- Plain text: https://secwatch.observer/filing/0001274737-22-000080.txt

## Key facts
- Executive change
  Debra Zack was terminated as Chief Medical Officer at EXAGEN INC..
  - Action: terminated
  - Role: Chief Medical Officer
  source text: On December 5, 2022, Debra Zack, M.D., Ph.D., the Company’s Chief Medical Officer, was removed from her position and her employment terminated in connection with the Reduction in Force.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000080/0001274737-22-000080-index.htm
- Executive change
  Mark Hazeltine was appointed as Chief Business Officer at EXAGEN INC..
  - Action: appointed
  - Role: Chief Business Officer
  source text: On December 5, 2022, Mark Hazeltine, the Company’s current Chief Operating Officer was appointed to serve as the Company’s Chief Business Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000080/0001274737-22-000080-index.htm
- Restructurings & Charges
  EXAGEN INC. announced a restructuring with charges of approximately $750,000 (42 employees).
  - Type: restructuring
  - Charge: approximately $750,000
  - Headcount: 42 employees
  source text: On December 5, 2022, the Board of Directors of Exagen Inc. (the “Company”) approved a reduction in force intended to conserve the Company’s current cash resources. The Company will reduce its current workforce by 42 employees (the “Reduction in Force”). The Company estimates that it will incur aggregate pre-tax charges of approximately $750,000 in connection with the reduction in force, primarily consisting of notice period and severance payments, employee benefits and related costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000080/0001274737-22-000080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.